GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NeoGenomics Inc (NAS:NEO) » Definitions » Price-to-Owner-Earnings
中文

NeoGenomics (NeoGenomics) Price-to-Owner-Earnings

: (As of Today)
View and export this data going back to 1996. Start your Free Trial

As of today (2024-04-23), NeoGenomics's share price is $14.25. NeoGenomics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for NeoGenomics's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of NeoGenomics was 655.83. The lowest was 33.10. And the median was 121.22.


NEO's Price-to-Owner-Earnings is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 24.76
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-23), NeoGenomics's share price is $14.25. NeoGenomics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.70. Therefore, NeoGenomics's PE Ratio for today is At Loss.

As of today (2024-04-23), NeoGenomics's share price is $14.25. NeoGenomics's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.50. Therefore, NeoGenomics's PE Ratio without NRI for today is At Loss.

During the past 13 years, NeoGenomics's highest PE Ratio without NRI was 2408.70. The lowest was 0.00. And the median was 214.03.


NeoGenomics Price-to-Owner-Earnings Historical Data

The historical data trend for NeoGenomics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoGenomics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 284.33 - -

NeoGenomics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Diagnostics & Research subindustry, NeoGenomics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeoGenomics Price-to-Owner-Earnings Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, NeoGenomics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where NeoGenomics's Price-to-Owner-Earnings falls into.



NeoGenomics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

NeoGenomics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=14.25/-0.56
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NeoGenomics  (NAS:NEO) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


NeoGenomics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of NeoGenomics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


NeoGenomics (NeoGenomics) Business Description

Traded in Other Exchanges
Address
9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.
Executives
Alicia C Olivo officer: General Counsel 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Anthony P. Zook director C/O VIVUS, INC., 351 EAST EVELYN AVENUE, MOUNTAIN VIEW CA 94041
Elizabeth Floegel director 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Neil Gunn director 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Greg D Aunan officer: Chief Accounting Officer HMS HOLDINGS CORP., 5615 HIGH POINT DRIVE, IRVING TX 75038
Jeffrey Scott Sherman officer: Chief Financial Officer 103 POWELL COURT, SUITE 200, BRENTWOOD TN 37027
Melody Harris officer: President, Enterprise Ops 4801 WEST BYRON PLACE, DENVER CO 80211
Warren Stone officer: President, Clinical Services 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
David Brian Perez director 12100 6TH AVENUE, LAKEWOOD CO 80228
Christopher M Smith officer: Chief Executive Officer 125 CONSTITUTION DRIVE, MENLO PARK CA 94025
Shashikant Kulkarni officer: President of Lab Operations 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Vishal Sikri officer: President and CCO, Inivata 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
David Sholehvar officer: President, Clinical Services 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
William Bonello officer: VP, Investor Relations 12780 WESTLINKS DRIVE, FORT MYERS FL 33913
Kathryn B Mckenzie officer: Principal Accounting Officer 12780 WESTLINKS DRIVE, FORT MYERS FL 33913